129 related articles for article (PubMed ID: 12559499)
1. Clinical and laboratory characteristics of secondary progressive MS.
Palace J
J Neurol Sci; 2003 Feb; 206(2):131-4. PubMed ID: 12559499
[TBL] [Abstract][Full Text] [Related]
2. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.
Whitaker JN; Wolinsky JS; Narayana PA; Bartolucci AA; Noseworthy JH; Lublin FD; Linde A; Gjörstrup P; Sullivan HC;
Arch Neurol; 2001 Jan; 58(1):49-54. PubMed ID: 11176936
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory features of primary progressive and secondary progressive MS.
Bashir K; Whitaker JN
Neurology; 1999 Sep; 53(4):765-71. PubMed ID: 10489038
[TBL] [Abstract][Full Text] [Related]
4. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
Whitaker JN; Layton BA; Bartolucci AA; Mitchell GW; Bashir K; Goodwin J; Kachelhofer RD
Arch Neurol; 1999 Jun; 56(6):687-91. PubMed ID: 10369307
[TBL] [Abstract][Full Text] [Related]
5. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
6. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.
Vukusic S; Confavreux C
J Neurol Sci; 2003 Feb; 206(2):135-7. PubMed ID: 12559500
[TBL] [Abstract][Full Text] [Related]
8. Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report.
Giordano A; Colombo B; Spinelli EG; Gelibter S; Guerrieri S; Leocani L; Comi G; Martinelli V
Mult Scler Relat Disord; 2018 Aug; 24():69-71. PubMed ID: 29957351
[TBL] [Abstract][Full Text] [Related]
9. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
10. Cortical sources of resting state electroencephalographic rhythms differ in relapsing-remitting and secondary progressive multiple sclerosis.
Babiloni C; Del Percio C; Capotosto P; Noce G; Infarinato F; Muratori C; Marcotulli C; Bellagamba G; Righi E; Soricelli A; Onorati P; Lupattelli T
Clin Neurophysiol; 2016 Jan; 127(1):581-590. PubMed ID: 26111485
[TBL] [Abstract][Full Text] [Related]
11. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
[TBL] [Abstract][Full Text] [Related]
12. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
[TBL] [Abstract][Full Text] [Related]
13. [Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach].
Vécsei L
Ideggyogy Sz; 2021 Jul; 74(7-08):249-255. PubMed ID: 34370413
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing-Remitting from Secondary Progressive Multiple Sclerosis. A Review.
Pietrasik S; Dziedzic A; Miller E; Starosta M; Saluk-Bijak J
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769314
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic aspects of multiple sclerosis and future therapeutic options.
Jamebozorgi K; Rostami D; Pormasoumi H; Taghizadeh E; Barreto GE; Sahebkar A
Int J Neurosci; 2021 Jan; 131(1):56-64. PubMed ID: 32075477
[TBL] [Abstract][Full Text] [Related]
16. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
Silber E; Semra YK; Gregson NA; Sharief MK
Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
[TBL] [Abstract][Full Text] [Related]
17. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
18. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis.
Whitaker JN; Kachelhofer RD; Bradley EL; Burgard S; Layton BA; Reder AT; Morrison W; Zhao GJ; Paty DW
Ann Neurol; 1995 Oct; 38(4):625-32. PubMed ID: 7574459
[TBL] [Abstract][Full Text] [Related]
19. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
[TBL] [Abstract][Full Text] [Related]
20. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA
Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
